# Rootine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rootine

- Industry: Healthcare IT
- Headquarters: Nashville, US
- Website: www.rootine.co
- Total disclosed funding: $11M
- Latest round: Series A (Jul 5, 2022)
- Investors on record: 7

## About

Based in Tennessee, the US, and founded in 2018, Claya Inc., dba Rootine, offers personalized health and nutrition solutions. In September 2022, Rootine raised USD 10 million in Series A funding from Relevance Ventures, Techstars, and DSM Venturing. Daniel Wallerstorfer and Rachel Soper Sanders (CEO) are the co-founders of the company.

The company enables users to test their bodies, get actionable insights by analyzing health data, take personalized micronutrients, and track progress via a mobile app. The firm's analysis covers micronutrient deficiencies such as fatigue, brain fog, productivity loss, mood imbalance, and more. The company's products include precision multivitamins, blood vitamin tests, blood mineral tests, DNA tests, DNA + blood test bundles, and three test bundles.

Rootine generates revenue by charging a monthly subscription fee that starts at USD 69.

The organization plans to use the September 2022 funding to hire new employees, forge partnerships, create new distribution channels, democratize access to at-home lab testing, invest in R&D of precision nutrition solutions, and expand its offerings.

## Funding rounds

- Series A, Jul 5, 2022, $6.8M — DSM Venturing, Techstars, Relevance Ventures
- Seed, Apr 13, 2021, $4.1M — DSM Venturing, Cleo Capital, Launch Tennessee, Duro Ventures, Novogenia

## Investors

- DSM Venturing (https://capitalatlas.ai/funds/dsm-venturing) — Seed, Series A
- Cleo Capital (https://capitalatlas.ai/funds/cleo-capital) — Seed
- Launch Tennessee (https://capitalatlas.ai/funds/launch-tennessee) — Seed
- Duro Ventures (https://capitalatlas.ai/funds/duro-ventures) — Seed
- Novogenia — Seed
- Techstars (https://capitalatlas.ai/funds/techstars) — Series A
- Relevance Ventures (https://capitalatlas.ai/funds/relevance-ventures) — Series A